-
-
B336621-100mgBohemine is a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor (IC|50|= 1 μM) that is structurally similar to Olomoucine and Roscovitine . Arrests cell cycle in the G1/S boundary and activates in vitro matured bovine oocytes either
-
B336621-1mgBohemine is a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor (IC|50|= 1 μM) that is structurally similar to Olomoucine and Roscovitine . Arrests cell cycle in the G1/S boundary and activates in vitro matured bovine oocytes either
-
B336621-25mgBohemine is a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor (IC|50|= 1 μM) that is structurally similar to Olomoucine and Roscovitine . Arrests cell cycle in the G1/S boundary and activates in vitro matured bovine oocytes either
-
B336621-5mgBohemine is a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor (IC|50|= 1 μM) that is structurally similar to Olomoucine and Roscovitine . Arrests cell cycle in the G1/S boundary and activates in vitro matured bovine oocytes either
-
-
-
-
-
B413622-1mgInformationBozitinib (PLB-1001) Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in
-
B413622-25mgInformationBozitinib (PLB-1001) Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in
-
B413622-50mgInformationBozitinib (PLB-1001) Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in